Key Points
- Progyny EVP Allison Swartz sold 3,903 shares at an average price of $26.10, generating approximately $101,868. The transaction, conducted under a Rule 10b5-1 plan, reduced her ownership by 4.9% to 75,816 shares.
- Progyny reported quarterly EPS of $0.55, exceeding the $0.33 analyst consensus, while revenue reached $350.51 million, up 5.3% year over year. The company provided Q3 and full-year 2026 EPS guidance.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $34.36, while institutional investors own 94.93% of the company’s stock.
Progyny, Inc. (NASDAQ:PGNY - Get Free Report) EVP Allison Swartz sold 3,903 shares of Progyny stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total transaction of $101,868.30. Following the completion of the sale, the executive vice president owned 75,816 shares of the company's stock, valued at $1,978,797.60. This trade represents a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Progyny Stock Performance
Shares of NASDAQ PGNY opened at $25.52 on Tuesday. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $33.06. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 27.74, a P/E/G ratio of 1.76 and a beta of 0.99. The business's 50-day simple moving average is $27.64 and its 200-day simple moving average is $24.64.
Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, topping analysts' consensus estimates of $0.33 by $0.22. The business had revenue of $350.51 million during the quarter, compared to analysts' expectations of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. Progyny's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities research analysts forecast that Progyny, Inc. will post 1.25 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on PGNY shares. Leerink Partners set a $38.00 price objective on Progyny in a report on Wednesday, July 22nd. BTIG Research boosted their price objective on Progyny from $30.00 to $40.00 and gave the stock a "buy" rating in a report on Friday, July 24th. KeyCorp increased their price target on shares of Progyny from $30.00 to $35.00 and gave the company an "overweight" rating in a research report on Monday, July 13th. JPMorgan Chase & Co. increased their target price on shares of Progyny from $27.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, August 21st. Finally, Zacks Research upgraded Progyny from a "hold" rating to a "strong-buy" rating in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $34.36.
Get Our Latest Research Report on PGNY
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Hsbc Holdings PLC bought a new stake in shares of Progyny during the 2nd quarter worth about $760,000. AWM Investment Company Inc. acquired a new stake in Progyny during the second quarter worth approximately $6,343,000. Easterly Investment Partners LLC grew its position in Progyny by 197.4% during the fourth quarter. Easterly Investment Partners LLC now owns 146,013 shares of the company's stock worth $3,750,000 after buying an additional 96,912 shares in the last quarter. Bank of America Corp DE increased its stake in Progyny by 75.3% during the 1st quarter. Bank of America Corp DE now owns 1,190,996 shares of the company's stock worth $20,223,000 after acquiring an additional 511,609 shares during the period. Finally, Royal Bank of Canada increased its stake in Progyny by 98.0% during the 1st quarter. Royal Bank of Canada now owns 218,434 shares of the company's stock worth $3,709,000 after acquiring an additional 108,137 shares during the period. 94.93% of the stock is owned by institutional investors and hedge funds.
Progyny Company Profile
(
Get Free Report)
Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.
The company's services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.
Progyny primarily serves employer-sponsored benefit programs in the United States.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
